DHL Supply Chain is to make further investments to strengthen its life sciences and healthcare capabilities in North America. The company announced that it has committed more than $70m to develop additional specialised warehousing infrastructure and deploy new technologies in support of its pharmaceutical and medical devices customers. The latest commitment builds on the $150m investment that DHL Supply Chain announced in June 2019 to expand its US distribution network for the industry and bring critical healthcare products closer to trade partners and patients.
DHL Supply Chain currently operates 30 specialised facilities with over 11m sq ft of temperature-controlled and certified infrastructure in the US. The new investment will include the development of new customer sites in Memphis, TN and Indianapolis, IN as well as the deployment of emerging technologies, such as the LocusBots collaborative robots that enhance picking productivity rates and site throughput. The company announced plans earlier this year to increase its fleet of LocusBots to 1,000 by the end of this year.
More than 9,000 specialists work across DHL’s dedicated global network so that pharmaceutical, medical devices, clinical trials and research organizations, wholesalers and distributors, as well as hospitals and healthcare providers are connected across the value chain.
Scott Cubbler, President of Life Sciences and Healthcare at DHL Supply Chain North America, said, “By making this investment, which will also allow us to expand the use of efficiency-boosting new technologies, we are providing our customers with a platform for further growth, as well as the flexibility they need to respond as essential services in a fast-changing environment.”
Source: DHL
